Current Collaborations

The Rapid Prospective Evaluation (RapidEval) Unit within the Healthcare Innovation Program for Implementation & Evaluation of the Center for Learning Health System Sciences focuses on the rapid evaluation of healthcare innovations taking place within the healthcare system. The goal of RapidEval is to increase adoption of best practices by facilitating rigorous evaluation of novel approaches to healthcare delivery.

co-Leads: Mike Usher, Joe Koopmeiners

The overall goal is to successfully scale, evaluate, and maintain an interoperable traumatic brain injury (TBI) clinical decision support (CDS) across a 4-institution collaborative network. This study will conduct a Hybrid Type 2 randomized stepped wedge effectiveness-implementation trial to assess the effect of CDS implementation on patient-level adherence with the clinical practice guidelines and venous thromboembolism event rate in patients with TBI.

PIs: Chris Tignanelli, Genevieve Melton-Meaux

Funding: NIH R18-HS028583

The SMART Explicit Study (SES) is a randomized clinical trial that compares the efficacy and efficiency of an innovative intervention that combines explicit and implicit approaches (Explicit-added) to a traditional implicit treatment approach (Implicit-only) to teach grammatical forms to children with developmental language disorder. To learn how to optimize treatment, the study will compare sequences of Explicit-added and Implicit-only treatments using a Sequential Multiple Assignment Randomized Trial (SMART) design. Participants will include 5- through 8-year-old children with DLD with grammatical weaknesses.

PIs: Liza Finestack

Funding: NIH R01-DC019374

The overall purpose of this study is to generate data that will be used to inform the development of an adaptive intervention for the treatment of adolescent severe obesity that includes empirically-derived decision rules which address when to start anti-obesity medications in patients who are not responding to lifestyle therapy (i.e., after 12-weeks or 24-weeks) and how to modify pharmacotherapy when there is a sub-optimal response to the initial pharmacological intervention (i.e., add topiramate to phentermine or switch to topiramate monotherapy). This study uses a two-stage sequential multiple assignment randomized trial (SMART) design.

PIs: Claudia Fox

Funding: NIH R01-DK119456

STOP-Sepsis is a randomized, placebo controlled, phase 2 clinical trial evaluating the use of fisetin, a senolytic agent, for the treatment of sepsis in older, hospitalized patients not yet requiring mechanical ventilation or vasopressors. STOP-Sepsis will use response adaptive randomization to identify the optimal dose of fisetin for future study in a future phase 3 clinical trial.

PI: Mike Puskarich

Funding: NIH U01-AG076929